Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Affiliations

• ¹ Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals Trust, Leeds, UK. rdetute@nhs.net.
• ² Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. g.cook@leeds.ac.uk.
• ³ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
• ⁴ Department of Haematology, Barts & The London NHS Trust, London, UK.
• ⁵ Mid-Yorks NHS Trust, Wakefield, UK.
• ⁶ Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust & Department of Endocrinology & Metabolism, University of Sheffield, Sheffield, UK.
• ⁷ Department of Haematology, University College London, London, UK.
• ⁸ Department of Clinical Haematology, Manchester Royal Infirmary, Manchester Foundation Trust, Manchester, UK.
• ⁹ University Hospital Southampton NHS Foundation Trust, Southampton, UK.
• ¹⁰ Institute of Immunology and Immunotherapy University of Birmingham, Birmingham, UK.
• ¹¹ College of Myeloma, Belfast, UK.
• ¹² Haematological Malignancy Diagnostic Service, Leeds Teaching Hospitals Trust, Leeds, UK.